Drugs / GSK1024850A
GSK1024850A
also known as
Synflorix · SynflorixTM · GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate GSK1024850A (10Pn-PD-DiT) · GSK Biologicals´ Pneumococcal Conjugate Vaccine · GSK's 10-valent Pneumococcal Vaccine 1024850A · PHiD-CV · Synflorix vaccine
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00985751 | Nov 2009 → Oct 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT02447432 | Jun 2015 → Jan 2016 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01175083 | Jun 2011 → Jan 2013 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01153893 | Oct 2010 → Feb 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01119625 | Jul 2010 → Feb 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01030822 | Apr 2010 → Aug 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01027845 | Dec 2009 → Aug 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00985465 | Nov 2009 → Jun 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00907777 | Jun → Oct 2009 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00814710 | Mar → Nov 2009 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00829010 | Feb 2009 → Jun 2011 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00808444 | Jan → Nov 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00758264 | Oct 2008 → Jun 2009 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00652951 | Apr 2008 → May 2009 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00609492 | Jan → Nov 2008 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00496015 | Jul 2007 → Mar 2008 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00466947 | Jun 2007 → Aug 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00463437 | Apr 2007 → Jan 2008 | diphtheria, hepatitis B virus infection, pneumococcal infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00390910 | Oct 2006 → Jul 2007 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00344318 | Aug 2006 → Apr 2007 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01235949 | Nov 2010 → Mar 2012 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00970307 Background | Aug 2009 → Jan 2010 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00950833 Comparator | Aug 2009 → Sep 2010 | streptococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00792909 Comparator | Dec 2008 → Jul 2009 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK 1024850A | “GSK Biologicals' 10-valent pneumococcal conjugate (GSK1024850A) vaccine” NCT00970307 ↗24“10-valent pneumococcal vaccine (GSK 1024850A)” NCT00970307 ↗ |
| Known as | GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate GSK1024850A (10Pn-PD-DiT) | “GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate GSK1024850A (10Pn-PD-DiT)” NCT02447432 ↗ |
| Known as | GSK Biologicals´ Pneumococcal Conjugate Vaccine | “GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)” NCT00609492 ↗ |
| Known as | GSK's 10-valent Pneumococcal Vaccine 1024850A | “GSK's 10-valent Pneumococcal Vaccine 1024850A” NCT00463437 ↗ |
| Known as | PHiD-CV | “10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)” PMID 25008901 ↗ Jul 2014 |
| Known as | Synflorix | “clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh” NCT00808444 ↗2“GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)” NCT00652951 ↗ “GSK1024850A (Synflorix)” NCT01175083 ↗ |
| Known as | Synflorix vaccine | “10-valent pneumococcal conjugate candidate vaccine (Synflorix vaccine, or GSK1024850A)” NCT00466947 ↗ |
| Known as | SynflorixTM | “Subjects received SynflorixTM (GSK1024850A) intramuscularly in the right thigh co-administered with TritanrixTM-HepB/Hib intramuscularly in the left thigh at 6-10-14 weeks of...” NCT00814710 ↗1“GSK1024850A (SynflorixTM)” NCT01235949 ↗ |
| Modality | Vaccine | “10-valent Pneumococcal Conjugate Vaccine” NCT00390910 ↗ |
| Route | Intramuscular | “Intramuscular injection, 3 doses” NCT00390910 ↗ |